InSphero AG has announced the release of their new GravityTRAP™ Ultra-low Attachment (ULA) Plate. The automation-compatible 96-well ULA format expands InSphero's portfolio of tissue culture platforms ...
SCHLIEREN, Switzerland--(BUSINESS WIRE)--The United States Patent and Trademark Office (USPTO) has officially granted InSphero AG full protection of its GravityPLUS™ hanging drop technology. InSphero, ...
SCHLIEREN, Switzerland--(BUSINESS WIRE)--InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company is making their proprietary, patented 96- and 384-microwell plates ...
SCHLIEREN, Switzerland, Nov. 4, 2019 /PRNewswire/ -- InSphero AG today announced the company received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held ...
InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, will debut the GravityTRAP™ 384 Microtissue Platform at the Society ...
U-shaped microcavities made of PEG hydrogel ensure consistent, uniform organoid formation for reliable 3D culture results. InSphero Logo InSphero acquires DOPPL SA and Sun Bio’s Gri3D® platform, ...
SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ -- Akero Therapeutics and InSphero AG today announced that Akero has selected InSphero's 3D InSight™ Human Liver Disease Platform to ...
Insphero Partners With Chayon To Bring Advanced 3D In Vitro Technologies To South Korean Researchers
(MENAFN- EIN Presswire) InSphero has partnered with Seoul-based Chayon to provide 3D in vitro solutions for drug development to South Korean researchers. We are very pleased to welcome the Chayon team ...
(MENAFN- EIN Presswire) EINPresswire/ -- InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed the definitive agreement to acquire the DOPPL SA, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results